Utah Medical Products INC

Utah Medical Products, Inc. announced a revenue decline for the second quarter and first half of 2026 compared to the prior year, primarily due to the loss of sales to two major former customers.

Utah Medical Products, Inc. held its annual stockholder meeting on May 1, 2026, where key director elections and auditor ratification were approved.

Utah Medical Products, Inc. reported first quarter 2026 financial results consistent with projections, but showed a 10.2% decrease in revenue compared to the prior year, primarily due to the loss of a major China distributor.

Utah Medical Products, Inc. reported a decline in 2025 financial performance, missing projections, yet increased cash balances and raised its quarterly dividend.

Utah Medical Products, Inc. announced an increase in its quarterly cash dividend by 1.6% to $0.31 per share and appointed Kevin Timken to its expanded Board of Directors.

Utah Medical Products, Inc. reports a significant decline in third-quarter and nine-month 2025 financial results, primarily due to global trade uncertainty and distributor order cancellations.

Utah Medical Products Inc. reported a 10.2% decrease in Q1 2026 net sales compared to Q1 2025, primarily due to the loss of a major China distributor and lower international sales.

Utah Medical Products Inc. reported a significant drop in Q3 and nine-month net income and sales, primarily due to foreign trade events and distributor cancellations, leading to a revised full-year sales outlook.

Utah Medical Products reports a decline in Q2 and H1 2025 revenues and net income, primarily due to reduced sales to a major OEM customer and lower gross profit margins.

Utah Medical Products' Q1 2025 earnings decreased due to a significant drop in OEM sales, particularly to PendoTECH, despite growth in direct sales of NICU devices.

Utah Medical Products experienced a decrease in sales and earnings in the third quarter of 2024, primarily due to reduced OEM sales and Filshie Clip System sales, but maintained a strong balance sheet.

Utah Medical Products experienced a decrease in sales and earnings in the second quarter of 2024, primarily due to reduced demand from a major OEM customer and lower sales in key product categories.

Utah Medical Products Inc. reported a decline in 2025 revenues and net income, impacted by lost OEM sales and Filshie Clip litigation, despite maintaining strong cash reserves.

Utah Medical Products Inc. experienced a significant decrease in worldwide revenues and net income in 2024, primarily due to reduced OEM sales, declining Filshie clip sales, and ongoing product liability litigation.

Utah Medical Products experienced a decrease in revenue but an increase in net income for 2023, while anticipating a significant revenue decline in 2024 due to reduced OEM sales and other factors.

Director Paul O. Richins of Utah Medical Products Inc. acquired 150 shares of common stock on June 29, 2026, at a price of $73.07 per share.

Brian Koopman, Principal Financial Officer of Utah Medical Products, gifted 50 shares of common stock.

Utah Medical Products' Principal Financial Officer, Brian Koopman, was granted 500 employee stock options with an exercise price of $58.1, vesting through 2030.

Utah Medical Products' Principal Financial Officer, Brian Koopman, reported gifting 50 shares of common stock.

Utah Medical Products Director Paul O. Richins reported gifting 100 shares of common stock on August 25, 2025.

Brian Koopman, Principal Financial Officer of Utah Medical Products Inc., reports the acquisition of stock options.

Utah Medical Products, Inc. (UTMD) has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation.

Utah Medical Products (UTMD) is set to hold its 2025 Annual Meeting of Stockholders, focusing on the election of a new director, ratification of the accounting firm, and an advisory vote on executive compensation.

Utah Medical Products, Inc. has issued a supplement to its definitive proxy statement to correct the language for proposal 3 regarding executive compensation, ahead of the 2024 Annual Meeting of Stockholders.

Utah Medical Products, Inc. is holding its annual stockholder meeting on May 3, 2024, to vote on the re-election of two directors, ratify the selection of its accounting firm, and conduct an advisory vote on executive compensation.

Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a 14.12% beneficial ownership stake in Utah Medical Products, Inc.

The Vanguard Group reports 0% beneficial ownership in Utah Medical Products Inc. common stock following an internal realignment.

Brandes Investment Partners, L.P. has reported a 10.4% beneficial ownership stake in Utah Medical Products Inc., holding 333,204 common shares.

Brandes Investment Partners, L.P. has disclosed a 7.39% beneficial ownership stake in Utah Medical Products Inc. common shares.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.3% of Utah Medical Products Inc.'s common stock as of June 30, 2025.

Dimensional Fund Advisors LP has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Utah Medical Products Inc. common stock as of June 30, 2025.